A new trading day began on Friday, with Agios Pharmaceuticals Inc (NASDAQ: AGIO) stock price up 4.36% from the previous day of trading, before settling in for the closing price of $33.75. AGIO’s price has ranged from $26.50 to $62.58 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 4.89% over the last five years. Meanwhile, its annual earnings per share averaged -163.23%. With a float of $55.21 million, this company’s outstanding shares have now reached $57.16 million.
The firm has a total of 488 workers. Let’s measure their productivity. In terms of profitability, gross margin is 80.53%, operating margin of -1166.47%, and the pretax margin is 1967.15%.
Agios Pharmaceuticals Inc (AGIO) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Agios Pharmaceuticals Inc is 3.66%, while institutional ownership is 106.81%. The most recent insider transaction that took place on Feb 05 ’25, was worth 78,134. In this transaction Principal Accounting Officer of this company sold 2,272 shares at a rate of $34.39, taking the stock ownership to the 5,437 shares. Before that another transaction happened on Jan 06 ’25, when Company’s Chief Commercial Officer sold 2,804 for $32.18, making the entire transaction worth $90,233. This insider now owns 18,906 shares in total.
Agios Pharmaceuticals Inc (AGIO) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.85 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -163.23% per share during the next fiscal year.
Agios Pharmaceuticals Inc (NASDAQ: AGIO) Trading Performance Indicators
Here are Agios Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 11.56. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 55.29.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 11.40, a number that is poised to hit -1.76 in the next quarter and is forecasted to reach -5.98 in one year’s time.
Technical Analysis of Agios Pharmaceuticals Inc (AGIO)
Analysing the last 5-days average volume posted by the [Agios Pharmaceuticals Inc, AGIO], we can find that recorded value of 0.72 million was lower than the volume posted last year of 0.76 million. As of the previous 9 days, the stock’s Stochastic %D was 79.00%. Additionally, its Average True Range was 1.56.
During the past 100 days, Agios Pharmaceuticals Inc’s (AGIO) raw stochastic average was set at 12.29%, which indicates a significant decrease from 97.86% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 32.07% in the past 14 days, which was lower than the 65.41% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $35.22, while its 200-day Moving Average is $42.87. Now, the first resistance to watch is $35.76. This is followed by the second major resistance level at $36.31. The third major resistance level sits at $37.31. If the price goes on to break the first support level at $34.21, it is likely to go to the next support level at $33.21. Now, if the price goes above the second support level, the third support stands at $32.66.
Agios Pharmaceuticals Inc (NASDAQ: AGIO) Key Stats
With a market capitalization of 2.02 billion, the company has a total of 57,296K Shares Outstanding. Currently, annual sales are 36,500 K while annual income is 673,730 K. The company’s previous quarter sales were 10,730 K while its latest quarter income was -96,520 K.
